Company intelligence / Profile preview

Padagis

Minneapolis, Minnesota, United Statespadagis.com ↗

Ownership: Private
Employees: ~1300
Development stage: Commercial

Overview

Padagis specializes in developing and manufacturing high-quality generic prescription and OTC pharmaceutical products with a focus on extended topical formulations. The company has successfully launched first-to-file and first-to-market generics—including the first OTC naloxone nasal spray—helping to make medications more affordable for patients.

Therapeutic areas: GastroenterologyCardiovascularInfectious DiseasesWomen's Health
Modalities: Small moleculeTopical formulation (creams, ointments, gels, foams, sprays, patches)Nasal spraySuppositoryInhalable product
Industry: Biotech

Drug pipeline

1 asset

naloxone

Commercial

Indications: Opioid overdose

Partnerships

Licensing agreementsjoint ventures for marketing/distribution/product acquisition—specific partners not named publicly.

Beyond the preview

Go deeper on Padagis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Padagis.

Explore the full profile